Employees of the CIE carried out the works on creating bacterial strains producing different human cytokines, on optimizing the cultivation of genetically engineered microorganisms and isolation of highly-purified recombinant cytokines.

Genferon® is the first medicinal developed at CIE. It is successfully used in combined treatment of urogenital infections.

In September  2006 one more preparation was registered in the RF – Leocostim®, the first Russian rh–G-CSF, developed by teams of CIE and CIE scientific affiliate. The license for its production was obtained. The preparation is successfully used in clinics.

The CIE team developed their own technology of isolation of recombinant human IFN-α2, as well as technology of production of the liquid medicinal injection form based on rhIFN-α2 (algeron) to treat infectious and oncologic diseases.  Pre-clinical studies of the   substance of rhIFN-α2 and algeron were carried out. Activities on the preparation registration  started.

In 2004 CIE  received a grant of the American Government of 1 million 760 thousand dollars  for the development of the interferon-beta version.
 
Currently CIE is the basic  organization of the  project 2909р «Development of the technology of production of transmucose and liquid injection medicinal forms of IFN-beta and their testing in medical practice» and a participating organization in the project 2828р «Development of experimental and production technology of obtaining the substance, creating samples of medicinal forms, pre-clinical trials of the substance, structural  and functional study and production of modified forms with improved pharmacological properties of the recombinant L-asparaginase of  Erwinia carotovora», financed by ISTC.

Within the project 2909 the CIE team developed the technology of isolation and purification of rhIFN-beta, technology of production of the liquid injection medicinal form based on rhIFN-beta (ronbetal) to treat multiple sclerosis. The Ronbetal pre-clinical studies were carried out. A package of scientific and technical documents were submitted to the RF Ministry of Health to receive the authorization of the clinical trials of ronbetal and the rhIFN-beta substance. Activities on creating the transmucose medicinal form based on rhIFN-beta were started.